OOIR: Observatory of International Research

Papers

(The H4-Index of Journal of Global Antimicrobial Resistance is 36. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2020-03-01 to 2024-03-01.)

Article	Citations
Antibiotic use in food animals worldwide, with a focus on Africa: Pluses and minuses	217
2019 novel coronavirus (2019-nCoV) outbreak: A new challenge	215
Environmental antimicrobial resistance and its drivers: a potential threat to public health	144
Resistance to ceftazidime–avibactam and underlying mechanisms	131
A global perspective on the convergence of hypervirulence and carbapenem resistance in Klebsiella pneumoniae	108
Implementation of antimicrobial stewardship programmes in African countries: a systematic literature review	98
Phage therapy for treatment of virulent Klebsiella pneumoniae infection in a mouse model	90
Mupirocin resistance in Staphylococcus aureus: A systematic review and meta-analysis	79
Virulence evolution, molecular mechanisms of resistance and prevalence of ST11 carbapenem-resistant Klebsiella pneumoniae in China: A review over the last 10 years	74
Vitamin D deficiency and the COVID-19 pandemic	73
Reduced susceptibility mechanism to cefiderocol, a siderophore cephalosporin, among clinical isolates from a global surveillance programme (SIDERO-WT-2014)	69
Antibiotic resistance surveillance systems: A review	65
Antimicrobial activity of LysSS, a novel phage endolysin, against Acinetobacter baumannii and Pseudomonas aeruginosa	63
Possible application of high-dose vitamin C in the prevention and therapy of coronavirus infection	61
Resistance to ceftazidime/avibactam in infections and colonisations by KPC-producing Enterobacterales: a systematic review of observational clinical studies	60
Incidence of bacterial and fungal bloodstream infections in COVID-19 patients in intensive care: An alarming “collateral effect”	59
Challenges in the management of chronic wound infections	56
Comparative efficacy and safety of combination therapy with high-dose sulbactam or colistin with additional antibacterial agents for multiple drug-resistant and extensively drug-resistant Acinetobacte	55
Non-antibiotic antimicrobial agents to combat biofilm-forming bacteria	53
The lurking scourge of multidrug resistant Candida auris in times of COVID-19 pandemic	52
Procalcitonin as an antibiotic stewardship tool in COVID-19 patients in the intensive care unit	52
Exploring the future of infectious disease treatment in a post-antibiotic era: A comparative review of alternative therapeutics	52
Italian young doctors’ knowledge, attitudes and practices on antibiotic use and resistance: A national cross-sectional survey	51
Antimicrobial resistance of Aggregatibacter actinomycetemcomitans, Porphyromonas gingivalis and Tannerella forsythia in periodontitis patients	49
Presence of heavy metal resistance genes in Escherichia coli and Salmonella isolates and analysis of resistance gene structure in E. coli E308	46

A link between the newly described colistin resistance gene mcr-9 and clinical Enterobacteriaceae isolates carrying blaSHV-12 from horses in Sweden	45
Antibiotic treatment and antimicrobial resistance in children with urinary tract infections	44
A descriptive case series of pharmacokinetic/pharmacodynamic target attainment and microbiological outcome in critically ill patients with documented severe extensively drug-resistant Acinetobacter ba	43
Emergence of Escherichia coli harbouring mcr-1 and mcr-3 genes in North West Algerian farmlands	42
Bedaquiline: Current status and future perspectives	40
Carbapenemase-producing Gram-negative bacteria in aquatic environments: a review	40
Development of real-time PCR assay allowed describing the first clinical Klebsiella pneumoniae isolate harboring plasmid-mediated colistin resistance mcr-8 gene in Algeria	39
Carbapenem-resistant Klebsiella pneumoniae in ICU-admitted COVID-19 patients: Keep an eye on the ball	39
Cefiderocol for compassionate use in the treatment of complicated infections caused by extensively and pan-resistant Acinetobacter baumannii	38
Relationship between virulence factors and antimicrobial resistance in Staphylococcus aureus from bovine mastitis	37
Minocycline, focus on mechanisms of resistance, antibacterial activity, and clinical effectiveness: Back to the future	36